Takeda Pharmaceutical (TAK) Capital Expenditures (2018 - 2026)

Takeda Pharmaceutical's Capital Expenditures history runs 9 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 15.72% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 18.25% decrease from a year earlier, with the FY2026 full-year figure at $1.2 billion, down 11.3% from the prior year.
• Capital Expenditures improved to $1.9 billion in Q1 2026 per TAK's latest filing, from -$270.5 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $2.3 billion in Q1 2025 and bottomed at -$369.0 million in Q2 2024.
• The 5-year median for Capital Expenditures is -$270.5 million (2025), against an average of $378.7 million.
• Across the five-year window, Capital Expenditures climbed 24.09% in 2022 and tumbled 34.46% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at -$236.9 million in 2022, then tumbled by 34.46% to -$318.5 million in 2023, then gained by 6.88% to -$296.6 million in 2024, then increased by 8.78% to -$270.5 million in 2025, then soared by 820.43% to $1.9 billion in 2026.
• Per Business Quant, the three latest TAK Capital Expenditures figures stand at $1.9 billion (Q1 2026), -$270.5 million (Q4 2025), and -$272.1 million (Q3 2025).